Skip to main content
. 2022 Mar 11;21:38. doi: 10.1186/s12933-022-01470-3

Table 1.

General characteristics of the study participants according to the TyG index

Characteristic Total (N = 10,535) TyG index P-value
Q1 (n = 2650) Q2 (n = 2647) Q3 (n = 2590) Q4 (n = 2648)
Sex, n (%)  < 0.001
 Male 5121 (48.6) 1375 (51.9) 1256 (47.4) 1183 (45.7) 1307 (49.4)
 Female 5414 (51.4) 1275 (48.1) 1391 (52.6) 1407 (54.3) 1341 (50.6)
Age, years, median (IQR)  < 0.001
 Total 64.0 (59.0–70.0) 65.0 (60.0–71.0) 64.0 (59.0–69.0) 64.0 (59.0–69.0) 63.0 (57.0–68.0)
  ≤ 60 55.0 (51.0–58.0) 55.0 (51.0–58.0) 55.0 (52.0–58.0) 55.0 (52.0–58.0) 55.0 (51.0–57.0)
  > 60 67.0 (64.0–71.0) 68.0 (64.0–72.0) 67.0 (64.0–71.0) 67.0 (63.0–71.0) 67.0 (64.0–71.0)
SBP, mmHg, median (IQR) 140.0 (128.0–156.0) 139.0 (124.0–152.0) 140.0 (126.0–155.0) 140.0 (130.0–159.0) 141.0 (130.0–159.0)  < 0.001
DBP, mmHg, median (IQR) 83.0 (77.0–90.0) 80.0 (75.0–90.0) 82.0 (76.0–90.0) 83.0 (78.0–90.0) 84.0 (78.0–91.0)  < 0.001
CRP, mg/L, median (IQR) 4.2 (2.0–12.8) 4.1 (1.9–14.9) 4.3 (2.0–14.2) 4.0 (2.0–11.3) 4.5 (2.2–11.2)  < 0.001
FPG, mmol/L, median (IQR) 6.2 (5.3–8.1) 5.3 (4.8–5.9) 5.8 (5.1–6.8) 6.54 (5.6–8.1) 9.4 (7.0–12.6)  < 0.001
LDL-C, mmol/L, median (IQR) 2.8 (2.1–3.4) 2.5 (1.9–3.1) 2.8 (2.2–3.4) 3.0 (2.3–3.6) 2.8 (2.2–3.5)  < 0.001
HDL-C, mmol/L, median (IQR) 1.1 (0.9–1.3) 1.2 (1.0–1.4) 1.1 (0.9–1.3) 1.1 (0.9–1.2) 1.0 (0.8–1.1)  < 0.001
TG, mmol/L, median (IQR) 1.4 (1.0–2.1) 0.9 (0.7–1.0) 1.3 (1.1–1.5) 1.8 (1.5–2.1) 2.6 (2.0–3.5)  < 0.001
TC, mmol/L, median (IQR) 4.6 (3.8–5.4) 4.1 (3.4–4.9) 4.5 (3.8–5.2) 4.7 (4.0–5.5) 5.0 (4.2–5.7)  < 0.001
HbA1c, mmol/L, median (IQR) 6.0 (5.6–7.0) 5.7 (5.4–6.2) 5.9 (5.5–6.5) 6.1 (5.6–6.9) 7.1 (6.1–8.6)  < 0.001
TyG index 9.0 (8.5–9.4) 8.2 (8.0–8.4) 8.7 (8.6–8.8) 9.1 (9.0–9.3) 9.8 (9.6–10.2)  < 0.001
Smoking, n (%) 4590 (43.6) 1173 (44.3) 1121 (42.3) 1101 (42.5) 1195 (45.1)  < 0.001
Drinking, n (%) 5863 (55.7) 1457 (55) 1480 (55.9) 1421 (54.9) 1505 (56.8)  < 0.001
Hypertension, n (%) 8875 (84.2) 2114 (23.8) 2201 (24.8) 2241(25.3) 2319 (26.1)  < 0.001
Hyperlipidemia, n (%) 5770 (54.8) 690 (12.0) 961 (16.7) 1326 (23.0) 1981 (34.3)  < 0.001
Use of antihypertensives, n (%) 5239 (49.7) 1160 (43.8) 1240 (46.8) 1363 (52.6) 1476 (55.7)  < 0.001
Use of antilipidemic, n (%) 7787 (73.9) 1703 (64.3) 1947 (73.6) 2026 (78.2) 2111 (79.7)  < 0.001
CIMT, mm, median (IQR) 0.10 (0.09–0.12) 0.10 (0.09–0.12) 0.10 (0.09- 0.12) 0.10 (0.09–0.12) 0.10 (0.09–0.12) 0.742
Carotid artery plaque, n (%) 8079 (76.69) 1985 (74.91) 1996 (75.41) 2006 (77.45) 2092 (79.00)  < 0.001
Glucose regulation state, n (%)  < 0.001
 Normal glucose regulation 3756 (35.7) 1735 (65.5) 1160 (43.8) 654 (25.3) 207 (7.8)
 Prediabetes 2813 (26.7) 694 (26.2) 861 (32.5) 834 (32.2) 424 (16.0)
 Diabetes 3966 (37.6) 221 (8.3) 626 (23.7) 1102 (42.5) 2017 (76.2)
No. of carotid artery plaque, n (%)  < 0.001
 0 2456 (23.3) 665 (25.1) 651 (24.6) 584 (22.5) 556 (21)
 1 406 (3.9) 96 (3.6) 100 (3.8) 100 (3.9) 110 (4.2)
  ≥ 2 7673 (72.8) 1889 (71.3) 1896 (71.6) 1906 (73.6) 1982 (74.8)
Carotid artery plaque echo property, n (%)  < 0.001
 Hypoechoic plaque 497 (4.7) 114 (4.3) 131 (4.9) 130 (5) 122 (4.6)
 Isoechoic plaque 548 (5.2) 137 (5.2) 133 (5) 136 (5.3) 142 (5.4)
 Hyperechoic plaque 4792 (45.5) 1211 (45.7) 1162 (43.9) 1194 (46.1) 1225 (46.3)
 Mixture plaque 2242 (21.3) 523 (19.7) 570 (21.5) 546 (21.1) 603 (22.8)

Data are presented as median (interquartile) or number (proportion, %)

Q1: TyG index < 8.52, Q2: 8.52 ≤ TyG index < 8.93, Q2: 8.93 ≤ TyG index ≤ 9.40, Q4: TyG index > 9.40

TyG, triglyceride-glucose; SBP, systolic blood pressure; DBP, diastolic blood pressure; CRP, C-reactionprotein; FPG, fasting plasma glucose; TC, total cholesterol; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; HbA1c, glycated haemoglobin; IQR, interquartile range